Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1698-1704

  Dieci, M V ^a   Mathieu, M C ^b   Guarneri, V ^a,c   Conte, P ^a,c   Delaloge, S ^b,d   Andre, F ^b,d,e   Goubar, Aicha ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d INSERM   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Adjuvant chemotherapy; Anthracyclines; Breast cancer; Tumor infiltrating lymphocytes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; TAMOXIFEN; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; TAMOXIFEN; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84941623486     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv239     Document Type: Article

References (14)

1. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
2. Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001; 7: 3025-3030.
3. Ladoire S, Mignot G, Dabakuyo S et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011; 224: 389-400.
4. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
5. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
6. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-2966.
7. Arriagada R, Spielmann M, Koscielny S et al. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol 2005; 44: 458-466.
8. Salgado R, Denkert C, Demaria S et al. Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014. Ann Oncol 2014; 26: 259-271.
9. Conforti R, Boulet T, Tomasic G et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclinesbased chemotherapy: a biomarker study from two randomized trials. Ann Oncol 2007; 18: 1477-1483.
10. R Development Core Team. R R: A language and environment for statistical computing. Vienna, Austria: R Foudation for Statistical Computing. http://www.rproject.org/(20 May 2015, date last accessed).
11. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184.
12. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544-1550.
13. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-611.
14. Savas P, Caramia F, Teo ZL, Loi S. Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. Curr Opin Oncol 2014; 26: 562-567.